GGrantIndex
Sort

64,565 grants matching drug discovery

Mitogenic and Oncogenic Regulation of ERK/RSK Signaling

$669,027
John Blenis · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA

High-Throughput Screening Platform for Cancer Drug Discovery

$669,017
Anne Plochowietz · Palo Alto Research Center · R33 · FY2021 · CA

Systems Genetics of Adiposity Traits in Outbred Rats

$668,810
Leah Catherine Solberg Woods · Medical College Of Wisconsin · R01 · FY2015 · DK

Neuron-Keratinocyte Communication in the Epidermis in Normal and Diabetic Wound Healing

$668,797
Amy S Paller · Northwestern University At Chicago · R01 · FY2023 · AR

Advancing Knowledge Discovery for Postoperative Pain Management

$668,723
Tina Hernandez-Boussard · Stanford University · R01 · FY2019 · LM

Chemical disarming of drug resistance in Mycobacterium tuberculosis

$668,717
Christina Leigh Stallings · Washington University · R01 · FY2018 · AI

Non Alcoholic Steatohepatitis Clinical Research Network

$668,701
Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · U01 · FY2023 · DK

Data Coordination and Integration Center for LINCS-BD2K

$668,701
Avi Ma'ayan · Icahn School Of Medicine At Mount Sinai · U54 · FY2016 · HL

NEW ANTICANCER DRUGS FOR CULTURED AND COLLECTED MARINE O

$668,682
University Of California San Diego · U19 · FY2001 · CA

Measure the metabolic and genetic factors that determine M. Tuberculosis

$668,601
David Branch Moody · Brigham And Women'S Hospital · U19 · FY2021 · AI

Genetic Variation and Evolution of Artemisinin Resistance

$668,571
Dyann F Wirth · Harvard School Of Public Health · R01 · FY2015 · AI

A Reliable Switched Angle Spinning (SAS) Probe with Gradients (PFG) for Proteins in Solid-State NMR

$668,446
Francis David Doty · Doty Scientific, Inc. · R44 · FY2022 · GM

Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomas

$668,427
Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2024 · CA

MPS Qualifications Section

$668,403
Edward J Kelly · University Of Washington · U2C · FY2024 · TR

Targeting cardiovascular events to improve patient outcomes after sepsis

$668,389
Allan J. Walkey · Boston University Medical Campus · R01 · FY2021 · HL

Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates

$668,381
Matthew Swan Lawrence · Virscio, Inc. · R44 · FY2009 · NS

Novel molecular therapeutics for cystic fibrosis

$668,380
David E Sterner · Progenra, Inc. · R44 · FY2014 · HL

L1 retrotransposon-based mutagenesis for rat models of human diseases

$668,320
Eric M Ostertag · Transposagen Biopharmaceuticals, Inc. · R44 · FY2008 · RR

High-dimensional Modeling of PET for radiomic Biomarker Discovery

$668,225
Ani Eloyan · Brown University · R01 · FY2024 · AG

Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease

$668,220
Kin Sing Stephen Lee · Michigan State University · R01 · FY2025 · AG

Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes

$668,150
Charles A Gersbach · Duke University · U01 · FY2022 · HL

Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes

$668,150
Charles A Gersbach · Duke University · U01 · FY2019 · EB

Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes

$668,150
Charles A Gersbach · Duke University · U01 · FY2021 · HL

Animal Model and Microbiology Core

$668,131
Andrew Nelson · Hackensack University Medical Center · U19 · FY2025 · AI

Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders

$668,094
Gavin R Rumbaugh · Scripps Florida · R01 · FY2020 · MH